#USA #Clinical Trials #Series A Funding #New Castle #IgniteData

IgniteData's Successful Series A Funding Close

On November 4, 2025, IgniteData, a prominent player in intelligent clinical trial data automation, announced the successful completion of its oversubscribed Series A funding round, raising a total of $11 million. This capital will significantly aid IgniteData in expanding its global research site network and advancing its flagship product, Archer. The funding is also essential for accelerating innovations in generative AI-powered data automation that will substantially enhance the efficiency of clinical trials.

The Archer Platform

At the core of IgniteData's technology is its Archer platform, which facilitates the seamless transfer of clinical trial data from various source systems such as electronic health records (EHRs) to electronic data capture (EDC) systems and data warehouses. This groundbreaking solution alleviates the burden on trial sites and promotes faster trial timelines by automating data transfer processes.

With this recent funding, IgniteData plans to broaden its global footprint and continue its commitment towards utilizing large language models and intelligent data mapping techniques. These advancements aim to unlock previously inaccessible clinical data, streamlining trial operations and enhancing data quality for sponsors and sites alike.

Leading the Investment Round

The funding round was spearheaded by FCA Venture Partners, with Labcorp Venture Fund and Epsilon serving as primary investors. Notably, returning investors such as SpringTide and Oncology Ventures also participated, evidencing strong confidence in IgniteData's capabilities.

Welcoming new investors Thomas Tarnowski and Marc Vangerven, both of whom bring an impressive background in scaling healthcare and technology companies, alongside Andy Cooper, CEO of CluePoints, represents a powerful endorsement of IgniteData's mission. Their engagement not only signifies a vote of confidence but also enriches the team with critical expertise.

Voices from the Investors

Zach Taft, CEO of IgniteData, emphasized the critical nature of this funding, stating, "This round is about scale. The demand for smarter, faster clinical trials is exploding. With Labcorp and Epsilon joining as primary investors in our Series A, and with the addition of Thomas, Marc, and Andy to our team, we gain not just capital but also invaluable expertise and endorsement from leaders who have shaped this industry."

Megann Vaughn Watters, Vice President of New Ventures and Strategic Alliances for Labcorp, shared her excitement about investing in IgniteData: "At Labcorp, we see tremendous value in innovations that reduce site burden and enable more efficient, higher-quality clinical trials. We are thrilled to support IgniteData on their journey to transform the way hospitals, research sites, and sponsors transfer patient data for clinical research and trials."

Gregory Epstein, Managing Partner at Epsilon, also identified the transformative potential of IgniteData's intelligent data automation: "Epsilon is committed to advancing healthcare through cutting-edge technology and data-driven solutions. IgniteData's approach to intelligent data automation is transformative for clinical trials, and we are excited to support their continued growth and global expansion."

Returning investors have also shown strong support by increasing their investments. Ryan Morley, Partner at SpringTide, noted, "We backed IgniteData early because we believed in their vision to revolutionize clinical trials through intelligent automation. Today, we're doubling down because they've exceeded expectations."

IgniteData's Vision

IgniteData aims to revolutionize the clinical trial landscape through intelligent automation. By facilitating real-time and secure transfers of clinical data between healthcare providers and life science companies, IgniteData accelerates research and significantly reduces burdens on clinical sites. Their operations span premier research centers and partnerships with prominent pharmaceutical sponsors, while their innovative use of generative AI and intelligent data mapping is reshaping the future of clinical trial operations.

In a burgeoning era of reliance on technology in healthcare, IgniteData stands out as a transformative force, dedicated to enhancing the collaborative dynamics between clinical trial sites and sponsors, ultimately leading to faster and more efficient clinical research.